Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic cutaneous melanoma AJCC Stage IIIB to IV, not potentially curable with surgery~* BRAF or NRAS mutation in tumor tissue~* All patients enrolled should provide sufficient fresh or archival tumor sample at baseline to enable confirmation of BRAF or NRAS mutations and the additional analyses described in the protocol~* Evidence of measurable tumor disease as per RECIST~* WHO performance status of 0-2~* Adequate organ function and laboratory parameters~Exclusion Criteria:~* History or evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for CSR or RVO~* Patients with unstable CNS metastasis~* Prior treatment with a MEK- inhibitor~* Impaired cardiovascular function~* HIV, active Hepatitis B, and/or active Hepatitis C infection~* Pregnant or nursing (lactating) women~* Women of child-bearing potential UNLESS they comply with protocol contraceptive requirements~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BRAFV600 mutant, 45mg bid MEK162 (Type: EXPERIMENTAL): BRAFV600 mutant, 45mg bid MEK162
- NRAS mutant, 45mg bid MEK162 (Type: EXPERIMENTAL): NRAS mutant, 45mg bid MEK162
- BRAFV600 mutant, 60mg bid MEK162 (Type: EXPERIMENTAL): BRAFV600 mutant, 60mg bid MEK162

Based on this trial design, predict the completion outcome and termination type (if applicable).